Table 4.
Long term outcomes and potential harms
| Long Term Outcomes | Potential Harms | |||||
|---|---|---|---|---|---|---|
| Total LE | BC mortality/ 1000 women dx with BC |
% BC mortality reduction |
FP screens (avg/woman) |
FP biopsies (avg/woman) |
% Radiation-induced BC |
|
| BRCA1 | ||||||
| Clinical | ||||||
| Surveillance | 70.83 | 548 | n/a | n/a | n/a | n/a |
| DM30 | 72.07 | 448 | 18.3 | 1.5 | 0.2 | 0.6 |
| Alt30 | 72.55 | 427 | 22.1 | 4.3 | 0.5 | 0.6 |
| BRCA2 | ||||||
| Clinical | ||||||
| Surveillance | 76.06 | 439 | n/a | n/a | n/a | n/a |
| DM30 | 77.49 | 305 | 30.5 | 2.9 | 0.4 | 1.7 |
| Alt30 | 77.75 | 287 | 34.6 | 8.6 | 1.1 | 1.7 |
LE=life expectancy without quality adjustment or discounting; dx=diagnosed; BC=breast cancer; FP=false-positive